Sandoz stock gains 2.23% since latest report as margin outlook holds
Published on 11/06/2026 at 18:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth and margin trade-off
- Sandoz narrowed its 2026 sales-growth outlook while raising its core EBITDA margin target.
- Biosimilars remained the main growth engine, but supply execution and German market conditions remain key investor focus areas.
- Full-year 2026 results are scheduled for February 17, 2027.
Sandoz stock has gained 2.23 percent since the latest report, with the Lang & Schwarz quote rising from 89.52 euros at 11:19 CET to 91.52 euros at 18:30 CET on Friday, November 6, 2026. The move gives investors a fresh market reference while the company's revised 2026 outlook remains the central fundamental issue.
Sandoz narrowed its 2026 net-sales growth forecast to 5% to 6% at constant currencies from a previous mid-to-high single-digit range. The company cited short-term biosimilar supply constraints and more difficult temporary market conditions in Germany, according to an ad-hoc-news report.
Biosimilars support profitability
Third-quarter net sales increased 5% at constant currencies to USD 2.942 billion. Biosimilar sales rose 17% to USD 998 million and accounted for 34% of quarterly sales, while generics sales were stable at USD 1.944 billion.
Management raised its 2026 core EBITDA margin forecast to 23.0% to 23.5%. The earlier view called for an increase of about 100 basis points from the 21.7% margin recorded in 2025. Sandoz said the more favorable product mix and stronger operating performance supported the upgrade.
What investors should watch
The revised guidance leaves Sandoz's existing targets through 2028 and its 2030 ambition unchanged. Investors will therefore weigh the ability to ease temporary supply constraints and manage German market pressure against the profitability benefit of a stronger biosimilar mix.
Investors can follow the real-time quote of Sandoz stock for the latest market indication.
The SMI provides the relevant Swiss market context for Sandoz stock through current SMI market coverage.
Sandoz plans to publish its full-year 2026 results on February 17, 2027. More news and analyses on Sandoz stock.
Sandoz Group AG
- ISIN: CH1243598427
- Primary listing: SIX Swiss Exchange
- Lang & Schwarz quote: 91.52 euros at 18:30 CET on Friday, November 6, 2026
- Change since latest report: 2.23% from 89.52 euros at 11:19 CET on November 6, 2026
- 2026 sales outlook: 5% to 6% growth at constant currencies
- 2026 core EBITDA margin outlook: 23.0% to 23.5%
